1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBioinformatics Research Core (BRC) Microgrants is sponsored by Center of Regenerative Medicine, Washington University in St. Louis. Microgrants supporting bioinformatics data analysis and related services at the Bioinformatics Research Core.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Bioinformatics Research Core (BRC) Microgrants | Center of Regenerative Medicine | Washington University in St. Louis Proposals OPEN, rolling submission Decision within ~4-weeks after submission BRC Microgrants – Request for Applications The Center of Regenerative Medicine (CRM) provides full-service bioinformatics capabilities through its Bioinformatics Research Core (BRC).
To facilitate usage of the core and offset costs, the CRM will offer microgrants to be used for bioinformatics data analysis and other related services at the BRC. Eligibility and Specific Requirements Awardees must be faculty members at WashU and must be members of the Center of Regenerative Medicine. Proposals must advance the mission of the Center of Regenerative Medicine.
Microgrants of up to $1,650 each will be awarded, all of which must be spent at the Bioinformatics Research Core and which must be used within 6-months of the award. Awards may not be transferred. Micro-grants are not eligible for the CRM bioinformatics subsidy and will be charged at the standard hourly rate.
Questions may be addressed to Jason Huang ( huangjason@wustl. edu ) or Bo Zhang ( bzhang29@wustl. edu ).
Applications will be reviewed by an internal selection committee identified by the leadership of the Center of Regenerative Medicine. To apply for this award, please submit the following information as a single PDF document: NIH-style biographical sketch A research statement describing the proposed research, including relevance to the CRM mission.
Proposals should not exceed 1 page in length, using standard margins and 11-12 pt font (Arial or Times). Preliminary data are not required but may be included. A brief budget justification based on proposed usage and corresponding costs at the BRC, using estimates provided by the BRC.
For example, 13. 2 hours of RNA-seq data analysis x $125/hour = $1650. Compiled applications may be submitted on a rolling basis to, to: CRM Microrant Selection Committee Email: huangjason@wustl.
edu Bioinformatics Research Core (BRC) Microgrants Editing and Innovation Core (EiC) Microgrants CRM Fellows Postdoc Recruitment Program Human Cells, Tissues, and Organoids (hCTO) Core Microgrants T32 Postdoctoral Training in Regenerative Medicine CRM Distinguished Postdoctoral Scholars Program Rita Levi-Montalcini Postdoctoral Fellowship in Regenerative Medicine Postbaccalaureate Program in Developmental Biology, Cell Biology, & Regenerative Medicine
According to the current listing, eligibility includes: Faculty members at Washington University in St. Louis who are members of the Center of Regenerative Medicine. Confirm the full requirements in the official notice before applying.
The current listing shows up to $1,650. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Bioinformatics Research Core (BRC) Microgrants is funded by Center of Regenerative Medicine, Washington University in St. Louis. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Washington. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Prostate Cancer Research Program (PCRP) Data Science Award (DSA) is sponsored by Department of Defense, Defense Health Agency (DHA). This award supports research that develops or uses quantitative and analytical approaches, processes, and/or systems to obtain knowledge and insight from large and/or complex sets of prostate cancer data. This includes artificial intelligence and machine learning, bioinformatics, computational biology, digital pathology, epidemiology, and medical imaging. All applications must address one of the FY26 PCRP Overarching Challenges. [7, 9]
Advancing the European bio-based innovation enabled by biotechnology and biomanufacturing concepts is sponsored by European Commission — Horizon Europe. Expected Outcome: Project results are expected to contribute to all of the following expected outcomes: significant advance in the development of innovation in biotechnology, life sciences and/or biomanufacturing concepts, preparing future deployment of bio-based and bio-inspired processes, products and materials, as a basis for sustainable, fair, safe and circular value chains, contributing to decarbonisation, industrial competitiveness and the strategic autonomy of the EU and Associated Countries; improved environmental sustainability of the developed innovative bio-based solutions, with positive and quantifiable impact on climate and biodiversity, and circularity of the European bioeconomy via enhanced resource efficiency, including of biological feedstocks, water and energy, integrating bio-based sector to minimize and remediate waste production. Scope: Actions funded under this topic are relevant to the EU policies related to the European Commission communication on ‘Building the future with nature: Boosting Biotechnology and Biomanufacturing in the EU’, the Life Sciences Strategy, the upcoming EU Biotech Act, and Circular Economy Act, the EU strategy on research and technology infrastructure, the Clean Industrial Deal and the policies related to the digital transition (e.g. AI Act, etc.). It also contributes to the Start-ups and Scale-ups Strategy. Proposals should address the following activities: identify, select and develop further promising selected key technologies underpinning the bio-based innovation/industry, in particular R&D on synthetic/molecular biology, gene editing, metabolic engineering, microbiome [1] , and/or biofoundry approaches, covering all applications aiming at clean growth and environmental solutions. Advancing towards validation at a pilot-scale is encouraged, to enable future exploitation. The applications in health biotechnology, as well as the biofuel/bioenergy area are excluded, to avoid overlaps with Horizon Europe Clusters 1 and 5, respectively; ensure the integration of digital technologies (e.g. AI/Machine Learning, bioinformatics); advance the convergence of biotech and life sciences developed under the first point with Nature-based Solutions, e.g. for environmental applications, carbon sequestration [2] , biodiversity protection/enhancement, aligned with (bio-)circular economy principles (e.g. cascading biomass use), ensuring the environmental fate and sustainability is considered quantitatively at the earliest stage and ensuring safety to human health and environment is addressed and guaranteed; develop recommendations for policy makers and industrial actors, taking into account the available scientifically sound assessment of risks and benefits of the developed solutions. Proposals should involve SMEs – both as project beneficiaries and as external actors – and offer opportunities to newcomers (to Horizon Europe Cluster 6). Proposals should also engage with the civil society stakeholders such as NGOs and consumer organisations to seek stakeholder involvement and acceptance, thus advancing scale-up and facilitating future market uptake. Proposals need to ensure compliance with the ‘Do no significant harm’ (DNSH) principle. Proposals are encouraged to consider, where relevant, the data, expertise and services offered by European research infrastructures [3] , such as EMSO ERIC, EU-OPENSCREEN, ELIXIR, EMBRC ERIC, IBISBA. Efforts should be made to ensure that the data produced in the context of this topic is FAIR (Findable, Accessible, Interoperable and Re-usable). Cooperation with the parallel projects funded under topic HORIZON-CL6-2026-01-CIRCBIO-10: Bio-based innovation in society: supporting the sustainable way of living is encouraged, to benefit from synergies and avoid overlaps. Similarly, activities should benefit from synergies and avoid overlaps with ongoing projects, e.g. funded under the topic HORIZON-CL6-2022-CIRCBIO-02-05-two-stage: Life sciences and their convergence wi Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Food, Bioeconomy Natural Resources, Agriculture and Environment, Bio-based Innovation Systems in the EU Bioeconomy Keywords: Agricultural biotechnology, Bio-based products (products that are manufactured using biological material as feedstock) bio-based materials, bio-based plastics, biofuels, bio-based and bio-derived bulk and fine chemicals, bio-based and bio-derived novel materials, Biochemistry and molecular biology, Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation, Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials, Cell biology and molecular transport mechanisms, Cell biology, Microbiology, DNA synthesis, modification, repair, recombination, degradation, Environmental biotechnology, Environmental biotechnology related ethics, Environmental biotechnology, bioremediation, biodegradation, General biochemistry and metabolism, Industrial biotechnology, Natural resources exploration and exploitation, Other biological topics, Plant sciences, botany, Proteomics, RNA synthesis, processing, modification and degradation, Social innovation, Social sciences, interdisciplinary, bio-based, bio-product, bioeconomy, biofoundry, bioinformatics, biomanufacturing, bioproduct, biotechnology, environmental biotechnology, gene editing, industrial biotechnology, life sciences, microbiome, synthetic biology
Gates committed $540.2 million over a decade to the Institute for Health Metrics and Evaluation — the largest gift in University of Washington history — while IHME's federal grant income falls from $7.3 million to a projected $4.8 million. The gift is a case study in the anchor-funder model: what it can do that federal money cannot, and the concentration risk it quietly underwrites.
Read articleMeyer pulled $6.5 million from a $200 million endowment. Greater Washington has deployed $14.3 million and put more than $1 million into Bridge Grants for 21 organizations — explicitly including mergers and organizational sunsets. Boston is funding merger facilitation. Here is how to tell which product an RFP is offering, and how to apply for the one you actually want.
Read articleThe full ASPECT NOFO (DE-FOA-0003647) posted September 4, 2026, eleven days later than the Notice of Intent predicted. The real document splits $58 million across two topic areas with anticipated award counts of 0-7 and 0-3, a cost share that jumps from 20 percent to 50 percent mid-project, a mandatory five-page concept paper due October 9, and a university eligibility restriction that decides team structure before anyone writes a word.
Read article